- Home
- OSUR vs ENGN Comparison
OSUR vs ENGN Comparison
Compare OSUR & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- ENGN
- Stock Information
- Founded
- OSUR 2000
- ENGN 1999
- Country
- OSUR United States
- ENGN Canada
- Employees
- OSUR N/A
- ENGN N/A
- Industry
- OSUR Medical/Dental Instruments
- ENGN
- Sector
- OSUR Health Care
- ENGN
- Exchange
- OSUR Nasdaq
- ENGN Nasdaq
- Market Cap
- OSUR 223.0M
- ENGN 204.3M
- IPO Year
- OSUR 1986
- ENGN N/A
- Fundamental
- Price
- OSUR $3.00
- ENGN $3.15
- Analyst Decision
- OSUR Hold
- ENGN Buy
- Analyst Count
- OSUR 1
- ENGN 7
- Target Price
- OSUR $3.00
- ENGN $23.29
- AVG Volume (30 Days)
- OSUR 804.6K
- ENGN 74.0K
- Earning Date
- OSUR 08-05-2025
- ENGN 06-12-2025
- Dividend Yield
- OSUR N/A
- ENGN N/A
- EPS Growth
- OSUR N/A
- ENGN N/A
- EPS
- OSUR N/A
- ENGN N/A
- Revenue
- OSUR $161,626,000.00
- ENGN N/A
- Revenue This Year
- OSUR N/A
- ENGN N/A
- Revenue Next Year
- OSUR $6.20
- ENGN N/A
- P/E Ratio
- OSUR N/A
- ENGN N/A
- Revenue Growth
- OSUR N/A
- ENGN N/A
- 52 Week Low
- OSUR $2.36
- ENGN $2.65
- 52 Week High
- OSUR $4.92
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- OSUR 54.60
- ENGN 37.77
- Support Level
- OSUR $2.78
- ENGN $3.17
- Resistance Level
- OSUR $3.03
- ENGN $3.44
- Average True Range (ATR)
- OSUR 0.13
- ENGN 0.43
- MACD
- OSUR 0.01
- ENGN -0.04
- Stochastic Oscillator
- OSUR 58.93
- ENGN 16.67
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.